Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.71 USD | -0.73% | +1.50% | +12.92% |
05/06 | Immutep Completes Stock Offering | MT |
03/06 | Immutep, Merck Collaborate on Trial for Lung Cancer Therapy | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.92% | 386M | - | ||
+40.80% | 53.67B | B- | ||
+35.79% | 38.86B | A | ||
-8.05% | 38.76B | B | ||
-8.98% | 27.27B | C | ||
+10.69% | 25.91B | B- | ||
-16.21% | 20.29B | B | ||
+31.00% | 12.78B | B+ | ||
+28.51% | 12.18B | C+ | ||
-1.67% | 11.96B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- IMM Stock
- IMMP Stock
- Ratings Immutep ADR